grepcent public filings, reorganized for comparison

OLUMIANT — FDA application NDA207924

Application NDA207924 · type NDA · FDA status: approved · original approval 2018-05-31

Listed sponsor: ELI LILLY AND CO · LLY company profile · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

FDA application facts

ProductFDA-listed trade nameActive ingredientDosage formRouteStrengthMarketing statusTE codeRLD
001OLUMIANTBARICITINIBTABLETORAL2MGPrescriptionABYes
002OLUMIANTBARICITINIBTABLETORAL1MGPrescriptionABYes
003OLUMIANTBARICITINIBTABLETORAL4MGPrescriptionABYes

Product, form, strength, reference-drug and marketing-status fields: Drugs@FDA data files; TE and RLD fields: Orange Book data files. Retrieved 2026-08-07.

Orange Book patent and exclusivity listings

ListingProductDescriptive dateFlags/code
Patent 8420629001listed patent expiry date: 2029-03-10U-247
Patent 8420629002listed patent expiry date: 2029-03-10U-247
Patent 11806555001listed patent expiry date: 2031-11-02U-3500
Patent 11806555002listed patent expiry date: 2031-11-02U-3500
Patent 11806555003listed patent expiry date: 2031-11-02U-3500
Patent 9737469001listed patent expiry date: 2031-11-02U-3500
Patent 9737469002listed patent expiry date: 2031-11-02U-3500
Patent 9737469003listed patent expiry date: 2031-11-02U-3500
Patent 8158616001listed patent expiry date: 2032-05-31drug substance, drug product
Patent 8158616002listed patent expiry date: 2032-05-31drug substance, drug product
Patent 8158616003listed patent expiry date: 2032-05-31drug substance, drug product
Patent 11045474001listed patent expiry date: 2032-11-30U-3372
Patent 11045474002listed patent expiry date: 2032-11-30U-3372
Patent 11045474003listed patent expiry date: 2032-11-30U-3372
Patent 9089574001listed patent expiry date: 2032-11-30U-3372
Patent 9089574002listed patent expiry date: 2032-11-30U-3372
Patent 9089574003listed patent expiry date: 2032-11-30U-3372
NDA207924 FDA listing dates. Source: Drugs@FDA and FDA Orange Book.NDA207924 FDA listing dates. Source: Drugs@FDA and FDA Orange Book.NDA207924 FDA listing datesDescriptive regulatory dates only; no relationship to revenue or future sales is stated or implied.Source: Drugs@FDA and FDA Orange Book.Listed dateDated listing marker0.001.002.002018-05-311.002029-03-101.002031-11-021.002032-05-311.002032-11-301.00

Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.

Compound cross-links

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

Related pages

Sponsor company · FDA-approved application index

Peer clusters: Large-cap biopharma

Sources: Drugs@FDA · Orange Book · openFDA application record. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.